Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Goodwill & Intangibles (2016 - 2021)

Historic Goodwill & Intangibles for Capricor Therapeutics (CAPR) over the last 11 years, with Q1 2021 value amounting to $1083.0.

  • Capricor Therapeutics' Goodwill & Intangibles fell 7999.26% to $1083.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $1083.0, marking a year-over-year decrease of 7999.26%. This contributed to the annual value of $2165.0 for FY2020, which is 6666.67% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Goodwill & Intangibles of $1083.0 as of Q1 2021, which was down 7999.26% from $2165.0 recorded in Q4 2020.
  • Over the past 5 years, Capricor Therapeutics' Goodwill & Intangibles peaked at $130066.0 during Q1 2017, and registered a low of $1083.0 during Q1 2021.
  • For the 5-year period, Capricor Therapeutics' Goodwill & Intangibles averaged around $48107.1, with its median value being $38952.0 (2019).
  • Within the past 5 years, the most significant YoY rise in Capricor Therapeutics' Goodwill & Intangibles was 3458.98% (2017), while the steepest drop was 9295.39% (2017).
  • Quarter analysis of 5 years shows Capricor Therapeutics' Goodwill & Intangibles stood at $93048.0 in 2017, then crashed by 46.51% to $49772.0 in 2018, then plummeted by 86.95% to $6495.0 in 2019, then tumbled by 66.67% to $2165.0 in 2020, then tumbled by 49.98% to $1083.0 in 2021.
  • Its Goodwill & Intangibles stands at $1083.0 for Q1 2021, versus $2165.0 for Q4 2020 and $3248.0 for Q3 2020.